A Toll-like Receptor Agonist as an Adjuvant to Tumor Associated Antigens (TAA) Mixed With Montanide ISA-51 VG With Bevacizumab for Patients With Recurrent Glioblastoma

Trial Profile

A Toll-like Receptor Agonist as an Adjuvant to Tumor Associated Antigens (TAA) Mixed With Montanide ISA-51 VG With Bevacizumab for Patients With Recurrent Glioblastoma

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 15 May 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Poly ICLC (Primary) ; Keyhole limpet haemocyanin; Montanide ISA-51; Peptide vaccines
  • Indications Glioblastoma
  • Focus Pharmacodynamics; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 May 2017 Planned initiation date changed from 1 Jun 2017 to 1 Jul 2017.
    • 15 Mar 2017 Planned initiation date changed from 1 Mar 2017 to 1 Jun 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top